Next-generation sequencing (NGS) is a massively parallel sequencing method that offers scalability, high throughput, and high speed for genome-wide sequencing of nucleotides. Because it involves the preparation of material for the subsequent sequencing reaction, DNA presequencing is one of the most important processes in a common sequencing protocol. Globally, NGS is increasingly integrated into clinical laboratory analysis, testing and disease diagnosis in the healthcare industry. In pharmacogenomics, next-generation sequencing (NGS) is often used to accelerate the drug discovery process.
To Understand Business Strategies, Request for a Sample Report at: https://www.delvens.com/get-free-sample/next-generation-sequencing-ngs-market-trends-forecast-till-2030Delvens Industry Expert's Standpoint
The pandemic had a considerable impact on businesses globally, with nations like India and China bearing the brunt of the virus's outbreak Declining sequencing costs have increased the use of NGS in disease diagnosis. Various testing kits and testing services are emerging for the non-invasive prenatal testing, cancer diagnosis, genetic testing and more, leading the global market.
Key Findings
• The application segment is further fragmented into diagnostics, biomarkers & cancer, reproductive health, personalized medicine, agriculture & animal research, and other applications. The biomarker and cancer segment is expected to account for a larger market size during the forecast period due to increase in prevalence of cancer and advancement in technology in next generation sequencing. However, the personalized medicine segment is expected to witness considerable next generation sequencing market growth during the forecast period, due to surge in demand for drug treatment, advancement in R&D in healthcare sector, and rise in awareness for NGS testing in pharmaceutical and biotechnological industry.
• The product type segment is further bifurcated into Consumables, Platforms, Services and Nerve Blockers. The consumables segment is the largest market during the forecast period owing to development of technology in molecular genetics and surge in demand for novel pre-sequencing products and kits that execute DNA fragmentation, target enrichment, size selection, and others. However, the services segment is expected to witness considerable next generation sequencing market growth during the forecast period, due to advancement in technology based on SMRT sequencing, and increase in application of cloud computing for NGS data storage.

• The end user segment is further bifurcated into Academic and Research Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Other End Users. Academic & clinical research to account for a larger market size during the forecast period due to increase in application-based usage in these institutes and rise in oncology research. However, the pharmaceutical & biotechnology companies’ segment is expected to witness considerable market growth during the forecast period, due to increase in prevalence of chronic disease, and advancement in R&D in the next generation sequencing market for therapeutics, oncology, and genomics research.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. In North America, increasing number of genomics research projects, rising demand for new NGS platforms and growing use of NGS consumables are various factors projected to drive the growth.
To Grow Your Business Revenue, Make an Inquiry Before Buying at: https://www.delvens.com/Inquire-before-buying/next-generation-sequencing-ngs-market-trends-forecast-till-2030

Regional Analysis
North America to Dominate the Market
• North America is estimated to account for the largest market share during the forecast period. In North America, increasing number of genomics research projects, rising demand for new NGS platforms and growing use of NGS consumables are various factors projected to drive the growth.
Competitive Landscape
• 10X Genomics
• Agilent Technologies
• BGI Group
• Bio-Rad Laboratories Inc.
• Brooks Automation Inc.
• CD Genomics
• DNASTAR Inc.
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd.
• Illumina Inc.
• Macrogen Inc.
• New England Biolabs
• Novogene Corporation Inc.
• Oxford Nanopore Technologies
• Pacific Biosciences of California Inc.
• PerkinElmer Inc.
• Precigen Inc., (Intrexon Bioinformatics Germany GmbH)
• Promega Corporation
• Psomagen
• Qiagen
• Takara Bio
• Tecan Trading Group
• Thermo Fisher Scientific Inc.
• Zymo Research
Recent Developments
• In January, 2023, QIAGEN announced a strategic partnership with California-based population genomics leader Helix to advance next-generation sequencing companion diagnostics in hereditary diseases.

• In March, 2023, The company SOPHiA GENETICS announced a new partnership with Qiagen that will pair QIAseq reagent technology with the DDM platform to enhance tumor analysis through next-generation sequencing (NGS).
Direct Purchase of Research Report at: https://www.delvens.com/checkout/next-generation-sequencing-ngs-market-trends-forecast-till-2030